Leflunomide
Overview
Leflunomide is used for its immunosuppressant properties, in the treatment of moderate to severe active rheumatoid arthritis and in active psoriatic arthritis. The immunosuppressant properties are partly due to the action of its active metabolite A77-1726 in inhibiting pyrimidine synthesis. Leflunomide is under invastiagation for its use in organ and tissue transplantation.
Categories
- 2 Analgesics, antipyretics, NSAIDs, antigout, and antirheumatics
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Leflunomide's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 100 mg | 100 (100) | 24 hourly | PO | For 3 days. Then 10-20 mg QD for maintenance. |
Paedriatic Dosage (20kg)
|
| No data regarding the Paedriatic dosage details of Leflunomide is available. |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Leflunomide is available. |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Leflunomide
Back to top
Previous Drug Generic - Next Drug Generic